2027 Q1 Financial Results | Revenue: ¥2,439 million (YoY -2.3%)

Financial Performance Overview

Daken Medical Instruments' results for the first quarter of fiscal year 2027, ending March 2027, showed revenue of ¥2,439 million (down 2.3% YoY), with increased costs leading to operating income of ¥214 million (down 23.9%) and net income of ¥167 million (down 22.3%). Revenue was supported by increased sales of injection-related products, though declines in suction device sales and rising material costs pressured profit margins. The company’s financial position remains strong with total assets of ¥11,076 million and an equity ratio of 68.6%. Going forward, the company plans to focus on cost management and supplying high-quality products to improve profitability.

Outlook and Impact on Shareholders

The current period’s performance is generally in line with initial forecasts, with no revision necessary at this time. Continued efforts will be made to maintain stable sales and manage costs, supporting the supply of products that meet medical needs. The dividend forecast remains at ¥20.00 per share, the same as for fiscal year ending March 2026, reflecting ongoing shareholder return policies. The company aims to enhance profitability and achieve steady business growth, providing an attractive investment proposition.